TrialJournal of the American Society of Nephrology : JASN2017

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.

Karine Dahan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.